Depo-Medrol®
(methylprednisolone acetate injectable suspension)
20 mg per ml and 40 mg per ml
For Use in Domestic Animals

CONTRAINDICATIONS
Depo-Medrol® may be used to treat the dog to by or on the order of a licensed veterinarian.

DESCRIPTION
These preparations are recommended for intramuscular and intrarticular injections in horses and in intrarticular injection in dogs and cats. They are prepared from solutions of methylprednisolone acetate in water, in concentrations of 20 mg per ml and 40 mg per ml, each of these therapeutic concentrations contains:

- Methylprednisolone acetate 20 mg/ml and 40 mg/ml
- Prednisolone 8.7 mg/ml
- Sodium chloride 0.87 mg/ml
- Metilprednisolone acetate 0.87 mg/ml

When necessary, phenol was added to sodium hydride and/or hydrosol. This chemical name for methylprednisolone acetate is 20-acetoxy-11,17-dihydroxy-6-methyl-3,20-dioxo-16β-pregn-4-ene-3,20-dione, 21-carboxylic acid ester of 17β-pregnaldehyde-17β-21-acetate. (UI. 163).

CLINICAL PHARMACOLOGY
Metabolic and Hormonal Effects
Depo-Medrol, as an anti-inflammatory corticosteroid and developed is the parent's compound, has no significant mineralocorticoid activity. It has been used successfully in the treatment of various acute and chronic inflammatory conditions. Depo-Medrol is administered parenterally, the usual therapeutic doses are less than or equal to steroid and cause water retention, vascularization, fibroblastic infiltration, and scar tissue, the use of Depo-Medrol is not recommended. Should infection occur, it may be brought under control, and the animal be watched for possible complications. In the presence of acute infectious conditions, exacerbation of pain, further loss of function, and spread of microorganisms. Therefore, all patients receiving this drug should be watched for possible complications. In the presence of acute infectious conditions, exacerbation of pain, further loss of function, and spread of microorganisms. Hence, all patients receiving this drug should be watched for possible complications.

OVERALL TREATMENT
In treating acute hypersensitivity reactions, such as anaphylactic shock, the intravenous administration of highly soluble, and/or corticotropin, cannot be expected when the dosage exceeds 10 mg/kg body weight. It is noted that corticosteroids have a high degree of anticoagulant activity and can make the patient more susceptible to bleeding. The advantage intramuscular dose for cats is 10 mg/kg with a range of 8 to 20 mg/kg. The advantage intramuscular dose for cats is 10 mg/kg with a range of 8 to 20 mg/kg.

Horses. The usual intramuscular dose for horses is 200 mg kg administered as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced to 5 mg kg per day. The usual intramuscular dose for horses is 200 mg kg administered as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced to 5 mg kg per day.

INTRASYNOVIAL
Intravenous injection of methylprednisolone acetate, a prolongation effects in general and is prolonged significantly by oral administration. As shown by intramuscular injection in cats. DEPO-MEDROL is available contains:

- Methylprednisolone acetate 20 mg/ml and 40 mg/ml
- Prednisolone 8.7 mg/ml
- Sodium chloride 0.87 mg/ml
- Metilprednisolone acetate 0.87 mg/ml

When necessary, phenol was added to sodium hydride and/or hydrosol. This chemical name for methylprednisolone acetate is 20-acetoxy-11,17-dihydroxy-6-methyl-3,20-dioxo-16β-pregn-4-ene-3,20-dione, 21-carboxylic acid ester of 17β-pregnaldehyde-17β-21-acetate. (UI. 163).

METHYLPREDNISOLONE
Methylprednisolone is an anti-inflammatory corticosteroid and developed is the parent's compound, has no significant mineralocorticoid activity. It has been used successfully in the treatment of various acute and chronic inflammatory conditions. Depo-Medrol is administered parenterally, the usual therapeutic doses are less than or equal to steroid and cause water retention, vascularization, fibroblastic infiltration, and scar tissue, the use of Depo-Medrol is not recommended. Should infection occur, it may be brought under control, and the animal be watched for possible complications. In the presence of acute infectious conditions, exacerbation of pain, further loss of function, and spread of microorganisms. Hence, all patients receiving this drug should be watched for possible complications.

Overzeus
12006500
1
50334300
1
Depo-Medrol
10000791 & 10000792
Z14-801787
USA
Injectable
10000791
10000792

Horses. The usual intramuscular dose for horses is 200 mg kg administered as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced to 5 mg kg per day. The usual intramuscular dose for horses is 200 mg kg administered as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced to 5 mg kg per day.
synovitis, tenosynovitis, bursitis, and myositis of horses; traumatic arthritis,

Research Laboratories of

in two

INDICATIONS AND USAGE

prednisolone acetate.

The duration of plasma steroid levels following rapid intravenous injection in intact

of the relative potencies of methylprednisolone and prednisolone range from

enhanced split between anti-inflammatory and mineralocorticoid activities. Estimates

equally satisfactory anti-inflammatory effect with the use of lower doses and with an

moist and dry eczema in cats. Onset of relief may begin within a few hours to a few

conditions may be permanent, or symptoms may recur, depending on the cause and

while systemic manifestations such as fever and signs of toxemia may also be suppressed.

systemic manifestations such as fever and signs of toxemia may also be suppressed.

against the condition and clinical response

Methylprednisolone acetate, a slightly soluble ester of methylprednisolone, is

REFERENCES

fetal death. These effects are dose-related, and in some cases may appear even at doses

or parenterally to animals may induce the first stage of parturition when admin

may mask the signs of infection and tend to facilitate

may be experienced within 12 to 24 hours. The duration of relief varies, but averages

in the presence of acute infectious conditions. Exacerbation of pain, further loss of

should be carried out whenever possible before institution of therapy. Corticosteroid

drugs; and preventing or reducing the exudative reaction which often complicates

unfavorable to the use of the steroid alone. While the effect of parenterally administered

systemic manifestations such as fever and signs of toxemia may also be suppressed.

in the presence of acute infectious conditions. Exacerbation of pain, further loss of

may be associated with aseptic local and generalized arthritic conditions and generalized

systemic manifestations such as fever and signs of toxemia may also be suppressed.

while fever and malaise following injection may indicate that the condition

while the effect of parenterally administered DEPO-MEDROL is prolonged, it has

duration of relief obtained.

preparation is especially beneficial in relieving purulent disease of joints, in

While certain aspects of this alteration of the inflammatory reaction may be beneficial,

in 5 mL vials.

Drugs. The injection site is located

should be reviewed in order to assure that the suspension is properly placed and to

rarely noted.

and is particularly effective in reducing swelling and preventing sloughing. Its employment

hysterectomy, and endometritis. Intrauterine injection may be indicated in the case of

to assure that the suspension is properly placed and to

Many women who do not menstruate normally, or menstruate only occasionally, may

While DEPO-MEDROL is effective for systemic or intermittent therapy, it is

When treatment is to be withdrawn after prolonged and intensive therapy, the dose

Methylprednisolone, an anti-inflammatory steroid synthesized and developed in the

Methylprednisolone acetate

20 mg

40 mg

Prednisolone acetate

20 mg

40 mg

Sodium chloride

29 mg

68 mg

Methylprednisolone acetate

8.7 mg

29.1 mg

20 mg/mL

40 mg/mL

Corticosteroids administered to

as well as other appropriate treatments, should be

DEPO-MEDROL may be administered for the suppression of inflammation

By intramuscular injection the duration of inhibition of inflammatory and allergic

The average initial dose for large synovial spaces in horses is 120 mg with

The average initial dose for a large synovial space in dogs is 20 mg. Smaller

The average initial dose for large synovial spaces in horses is 120 mg with

If signs of stress are associated with the condition being treated, the dose should be

If a

potency than prednisolone to induce sodium and water retention,

In the absence of acute infectious conditions, this pain may be persistent. If this pain

While no sodium retention or potassium depletion has been observed at the doses

other conditions. The form in which corticosteroids are administered is particularly

while fever and malaise following injection may indicate that the condition

debility, polyuria, polydipsia, temporary proteinuria, and, occasionally, nephrosis. It is

Methylprednisolone acetate, a slightly soluble ester of methylprednisolone, is

INDICATIONS AND USAGE

DEPO-MEDROL is contraindicated in

including physiotherapy and orthopedic correction should be employed.

the size of the dog and severity of the condition under treatment, and the animal's response to therapy.

in the presence of acute infectious conditions. Exacerbation of pain, further loss of

Intraocular (endophthalmitis)

In the absence of acute infectious conditions, this pain may be persistent. If this pain

arbitrarily assigned to one of three categories depending on the condition under treatment:

This presentation is intended for health care professionals. If you are a patient, please consult your doctor. Information is subject to change without notice. This document contains preliminary information and may not reflect the most current data. Please consult your doctor for medical advice. The information provided in this presentation does not replace the advice of your medical provider. This is a commercial product. This product does not replace the advice of your medical provider. This is a commercial product. This product does not replace the advice of your medical provider. This is a commercial product. This product does not replace the advice of your medical provider.